{"id":"varicella-virus-vaccine-live","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":"10–15","effect":"Fever"},{"rate":"3–5","effect":"Varicella-like rash (vaccine strain)"},{"rate":"5–10","effect":"Myalgia"}]},"_chembl":null,"_dailymed":{"setId":"73eae9fc-507b-4c9c-883d-63eb2e3cc6f6","title":"PROQUAD (MEASLES, MUMPS, RUBELLA AND VARICELLA VIRUS VACCINE LIVE) INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a weakened (attenuated) form of varicella-zoster virus that replicates in the body at low levels, triggering T-cell and B-cell responses without causing severe disease. This immune priming allows the body to rapidly recognize and neutralize wild-type virus upon natural exposure, preventing chickenpox infection or reducing disease severity.","oneSentence":"This live attenuated vaccine stimulates the immune system to recognize and protect against varicella-zoster virus by inducing both cellular and humoral immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:47.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of varicella (chickenpox) in susceptible individuals"},{"name":"Post-exposure prophylaxis of varicella in non-immune individuals"}]},"trialDetails":[{"nctId":"NCT07473427","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-05-01","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07475000","phase":"PHASE3","title":"Second Dose of Varicella Vaccine in Healthy Children","status":"RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-01-28","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07415252","phase":"PHASE3","title":"SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years","status":"NOT_YET_RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-06-05","conditions":"Varicella (Chickenpox)","enrollment":780},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT03604406","phase":"PHASE2","title":"The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kevin Winthrop","startDate":"2014-05-08","conditions":"Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT06961721","phase":"PHASE4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-05","conditions":"Prevention of Herpes Zoster","enrollment":600},{"nctId":"NCT06891872","phase":"PHASE4","title":"Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2025-05","conditions":"Varicella (chickenpox), MMR Vaccine, DTaP Vaccine","enrollment":720},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT06801509","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-02-15","conditions":"Herpes Zoster","enrollment":540},{"nctId":"NCT05095701","phase":"PHASE4","title":"An Immunity Persistence Study of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-12-18","conditions":"Varicella","enrollment":703},{"nctId":"NCT06314724","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-02-29","conditions":"Varicella","enrollment":642},{"nctId":"NCT06484686","phase":"PHASE4","title":"An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-16","conditions":"Varicella","enrollment":414},{"nctId":"NCT06614816","phase":"PHASE3","title":"Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-02-10","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT06592456","phase":"PHASE3","title":"A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-07-21","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT05015686","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-09-30","conditions":"Varicella","enrollment":2400},{"nctId":"NCT05158777","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2022-02-13","conditions":"Varicella","enrollment":2480},{"nctId":"NCT04072497","phase":"PHASE1, PHASE2","title":"A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-20","conditions":"Herpes Zoster","enrollment":522},{"nctId":"NCT01911065","phase":"PHASE4","title":"T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Herpes Zoster","enrollment":54},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT04384016","phase":"PHASE4","title":"Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2021-04-17","conditions":"Chickenpox","enrollment":201},{"nctId":"NCT05839301","phase":"PHASE3","title":"A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2023-04-27","conditions":"Varicella","enrollment":1200},{"nctId":"NCT05669625","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2022-12-26","conditions":"Varicella","enrollment":12440},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT05460429","phase":"PHASE4","title":"Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-30","conditions":"Varicella","enrollment":37920},{"nctId":"NCT05470855","phase":"PHASE4","title":"Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-06","conditions":"Varicella","enrollment":45400},{"nctId":"NCT05664152","phase":"NA","title":"An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years","status":"UNKNOWN","sponsor":"GC Biopharma Corp","startDate":"2023-02","conditions":"Varicella Zoster Virus Infection","enrollment":250},{"nctId":"NCT05526820","phase":"PHASE4","title":"A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-04-08","conditions":"Varicella","enrollment":450},{"nctId":"NCT01600079","phase":"","title":"ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-15","conditions":"Herpes Zoster, Shingles","enrollment":1505647},{"nctId":"NCT00940940","phase":"PHASE4","title":"Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2009-10","conditions":"Kidney Transplant","enrollment":4},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT05150392","phase":"PHASE3","title":"An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2018-07-11","conditions":"Varicella","enrollment":1193},{"nctId":"NCT04334577","phase":"PHASE3","title":"Study on Efficacy of Attenuated Zoster Vaccine, Live","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2020-04-20","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT02538341","phase":"PHASE2","title":"Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2016-05","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis","enrollment":617},{"nctId":"NCT00851786","phase":"PHASE2","title":"Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-04-29","conditions":"Herpes Zoster, HIV Infections","enrollment":395},{"nctId":"NCT00001125","phase":"PHASE1","title":"Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Chickenpox","enrollment":60},{"nctId":"NCT00000837","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":127},{"nctId":"NCT00213304","phase":"PHASE3","title":"The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"1999-06","conditions":"Organ Transplantation, Immunosuppression","enrollment":21},{"nctId":"NCT00681031","phase":"PHASE4","title":"Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05-14","conditions":"Herpes Zoster","enrollment":96},{"nctId":"NCT01262300","phase":"PHASE1","title":"Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-11","conditions":"Immunosenescence, Shingles","enrollment":33},{"nctId":"NCT03843632","phase":"PHASE3","title":"Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-01","conditions":"Varicella","enrollment":150},{"nctId":"NCT03314103","phase":"PHASE3","title":"Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-10-06","conditions":"Herpes Zoster","enrollment":30000},{"nctId":"NCT03239873","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-17","conditions":"Varicella","enrollment":600},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT02114333","phase":"PHASE1","title":"Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-05","conditions":"Shingles, Herpes Zoster","enrollment":160},{"nctId":"NCT03016884","phase":"PHASE4","title":"Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2017-01","conditions":"Herpes Zoster","enrollment":87},{"nctId":"NCT02590068","phase":"NA","title":"Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination","status":"TERMINATED","sponsor":"Rockefeller University","startDate":"2015-12","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT02624375","phase":"PHASE4","title":"Immune Response to Shingles Vaccination","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-02","conditions":"Shingles","enrollment":10},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT00092430","phase":"PHASE3","title":"Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09-26","conditions":"Measles, Mumps, Rubella","enrollment":1200},{"nctId":"NCT02329457","phase":"PHASE2, PHASE3","title":"VZV Vaccine for Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2014-12","conditions":"Varicella Zoster Infection","enrollment":100},{"nctId":"NCT00226499","phase":"PHASE3","title":"Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-01","conditions":"Varicella, Chickenpox Vaccines","enrollment":5803},{"nctId":"NCT03114943","phase":"PHASE3","title":"Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2016-07-14","conditions":"Varicella","enrollment":516},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT00326183","phase":"PHASE4","title":"Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-26","conditions":"Hepatitis A, Measles, Mumps","enrollment":1800},{"nctId":"NCT00496327","phase":"PHASE3","title":"Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06-22","conditions":"Varicella","enrollment":100},{"nctId":"NCT00561080","phase":"PHASE3","title":"Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-26","conditions":"Prevention of : Herpes-Zoster","enrollment":759},{"nctId":"NCT00792623","phase":"PHASE2","title":"Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-08","conditions":"Varicella","enrollment":45},{"nctId":"NCT02519855","phase":"PHASE3","title":"Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-11","conditions":"Herpes Zoster","enrollment":882},{"nctId":"NCT02062502","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-07","conditions":"Varicella","enrollment":611},{"nctId":"NCT01527370","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-31","conditions":"Herpes Zoster, Shingles","enrollment":250},{"nctId":"NCT01506193","phase":"PHASE3","title":"Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02-06","conditions":"Rubella, Varicella, Measles","enrollment":716},{"nctId":"NCT00402831","phase":"PHASE3","title":"ProQuad® Intramuscular vs Subcutaneous","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Measles, Mumps, Rubella","enrollment":405},{"nctId":"NCT03555071","phase":"PHASE3","title":"A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2014-04-07","conditions":"Varicella","enrollment":1197},{"nctId":"NCT01573182","phase":"PHASE2","title":"Herpes Zoster Vaccine for Bone Marrow Transplant Donors","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2012-04","conditions":"Herpes Zoster","enrollment":8},{"nctId":"NCT02692066","phase":"","title":"Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2016-04","conditions":"Varicella, Transplants","enrollment":""},{"nctId":"NCT02444936","phase":"PHASE4","title":"ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors","status":"UNKNOWN","sponsor":"Louis Stokes VA Medical Center","startDate":"2015-05-01","conditions":"Shingles","enrollment":22},{"nctId":"NCT00432042","phase":"PHASE3","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-12","conditions":"Varicella, Measles, Mumps","enrollment":955},{"nctId":"NCT00322049","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-02","conditions":"Dengue","enrollment":51},{"nctId":"NCT02983656","phase":"","title":"Analysis on AEFI Surveillance Data for Live Attenuated Varicella Vaccine","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2016-11","conditions":"Varicocele","enrollment":394},{"nctId":"NCT02965404","phase":"PHASE1","title":"A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2016-04","conditions":"Varicella","enrollment":270},{"nctId":"NCT02981836","phase":"PHASE3","title":"A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2016-08","conditions":"Varicella","enrollment":5997},{"nctId":"NCT00560755","phase":"PHASE3","title":"Safety Study of ProQuad® rHA in Infants (V221-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-24","conditions":"Measles, Mumps, Rubella","enrollment":3388},{"nctId":"NCT02958345","phase":"PHASE4","title":"Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™","status":"COMPLETED","sponsor":"Tulane University","startDate":"2013-06","conditions":"Herpes Zoster, Fibrosis","enrollment":28},{"nctId":"NCT02408159","phase":"PHASE4","title":"Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy","status":"TERMINATED","sponsor":"Innovaderm Research Inc.","startDate":"2016-06","conditions":"Psoriasis","enrollment":3},{"nctId":"NCT03121638","phase":"PHASE1","title":"Safety Study of NBP608 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2012-11","conditions":"Varicella Zoster, Immunization; Infection","enrollment":150},{"nctId":"NCT03120364","phase":"PHASE3","title":"Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2015-09-09","conditions":"Herpes Zoster","enrollment":824},{"nctId":"NCT03116594","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-01-03","conditions":"Herpes Zoster","enrollment":675},{"nctId":"NCT03114982","phase":"PHASE2","title":"The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2016-05","conditions":"Varicella","enrollment":152},{"nctId":"NCT00550745","phase":"PHASE4","title":"ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Herpes Zoster","enrollment":11999},{"nctId":"NCT00822237","phase":"PHASE3","title":"Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Varicella","enrollment":598},{"nctId":"NCT01505647","phase":"PHASE3","title":"Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-04","conditions":"Herpes Zoster, Shingles","enrollment":498},{"nctId":"NCT00546819","phase":"PHASE2","title":"ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Herpes Zoster","enrollment":309},{"nctId":"NCT01245751","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04","conditions":"Herpes Zoster, Varicella-zoster Vaccine","enrollment":600},{"nctId":"NCT00535730","phase":"PHASE3","title":"ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Herpes Zoster, Pneumococcal Infection","enrollment":473},{"nctId":"NCT00534248","phase":"PHASE3","title":"Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Shingles","enrollment":22439},{"nctId":"NCT01556451","phase":"PHASE4","title":"ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-04","conditions":"Herpes Zoster, Shingles","enrollment":180},{"nctId":"NCT00839917","phase":"PHASE3","title":"A Study of ProQuad™ in Healthy Children in Korea (V221-023)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Measles, Mumps, Rubella","enrollment":30},{"nctId":"NCT00109343","phase":"PHASE3","title":"V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03","conditions":"Measles, Mumps, Rubella","enrollment":1027},{"nctId":"NCT00109122","phase":"PHASE2","title":"Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11","conditions":"Shingles","enrollment":180},{"nctId":"NCT00005009","phase":"PHASE1","title":"Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1998-02","conditions":"Kidney Transplant Recipients","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Varicella vaccine, VARIVAX®","Varivax"],"phase":"marketed","status":"active","brandName":"Varicella Virus Vaccine Live","genericName":"Varicella Virus Vaccine Live","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This live attenuated vaccine stimulates the immune system to recognize and protect against varicella-zoster virus by inducing both cellular and humoral immunity. Used for Prevention of varicella (chickenpox) in susceptible individuals, Post-exposure prophylaxis of varicella in non-immune individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}